Q-omics provides the consensus-scored PCDHA11 profile across patient tissues and cancer cell-line models. PCDHA11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PCDHA11 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PCDHA11 RNA expression shows 12,814 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, KIRC, and TGCT as cancer lineages where PCDHA11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHA11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHA11 survival associations across molecular data types. PCDHA11 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHA11 RNA expression–survival associations across cancer types. High PCDHA11 expression shows unfavorable associations in LUSC, CESC and STAD, but favorable associations in UVM, KIRC and KIRP. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for PCDHA11 RNA expression.
This table summarizes PCDHA11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHA11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHA11 shows lower tumor expression in KIRC, KICH and READ and higher tumor expression in LUAD, BRCA and CHOL. The KIRC box plot shows higher PCDHA11 RNA expression in normal versus tumor tissue (log2 FC = −0.608, t-test p < 0.001).
This table shows molecular features associated with PCDHA11 in patient tissues and cancer cell lines. In patient samples, PCDHA11 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHA11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
